The Basic and Translational Cancer Research Program at The Saban Research Institute of Children's Hospital Los Angeles is home to major, internal pediatric research consortia, more than at any other single pediatric institution.
New Approaches to Neuroblastoma Therapy (NANT) Consortium
This consortium of 15 leading children’s hospitals and universities across the US and Canada perform phase I and II studies developed by investigators of the PPG. It is the only consortium of its kind in the world. NANT studies include pharmacokinetics, pharmacodynamics, biologic and immunobiologic evaluations, and provision for specimen banking. NANT has opened 15 clinical trials and has accrued 281 patients to clinical trials, averaging 46 patients annually for the past four years.
Therapeutic Advances in Childhood Leukemia (TACL)
The Therapeutic Advances in Childhood Leukemia (TACL) consortium was established in the USC-CHLA Institute for Clinical Research (IPCR) to provide a means for carrying out early studies of new drugs in children with recurrent leukemia. The TACL consortium is an international multi-institution group (33 institutions) that works together to rapidly develop and carry out phase I/II clinical trials of new drugs and novel drug combinations in which there are pre-clinical data that support testing these new approaches in recurrent childhood leukemia.
A major goal of TACL clinical trials is to provide data supporting expanded clinical trials that will be proposed to the Children's Oncology Group (COG). This research is funded by the NIH (R01 and P01 awards) and also by other foundations.
The Head Start Consortium for Pediatric Brain Tumors (Head Start)
The Head Start Consortium for Pediatric Brain Tumors, which investigates alternative treatments for malignant tumors to protect cognitive development. This is a multi-institutional study to treat newly-diagnosed child less than 10 years old with malignant brain tumors. This study currently has 37 participating institutions.
A multi-year, multi-project investigation into the biology and therapy of pediatric brain tumors was awarded a grant from the Pediatric Brain Tumor Foundation. The goal: to improve understanding of childhood brain tumors and pave the way for new therapies.
We are furthering studies of neuroblastoma with a Program Project Grant from the NIH’s National Cancer Institute (NCI). Additionally, we are pursuing molecularly targeted cancer therapies under another NCI grant, part of its nationwide initiative called Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET).